Larimar Therapeutics (LRMR)
(Real Time Quote from BATS)
$7.51 USD
+0.36 (5.04%)
Updated Aug 8, 2024 01:31 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LRMR 7.51 +0.36(5.04%)
Will LRMR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LRMR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LRMR
The Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics
Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News
LRMR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study
Nektar Therapeutics (NKTR) Q1 Earnings & Revenues Beat
Larimar (LRMR) Upgraded to Strong Buy: What Does It Mean for the Stock?
Other News for LRMR
Commit To Purchase Larimar Therapeutics At $5, Earn 20.3% Annualized Using Options
Larimar Therapeutics GAAP EPS of -$0.34
Larimar: Q2 Earnings Snapshot
Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results
Larimar Therapeutics plans PK run-in study in adolescents, children with FA